These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 9130684)

  • 1. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
    Momparler RL; Côté S; Eliopoulos N
    Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
    Momparler RL; Côté S; Eliopoulos N
    Leukemia; 1997 Feb; 11(2):175-80. PubMed ID: 9009076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).
    Momparler RL
    Semin Oncol; 2005 Oct; 32(5):443-51. PubMed ID: 16210084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
    Hurtubise A; Momparler RL
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):618-25. PubMed ID: 16783580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine.
    Karpf AR; Moore BC; Ririe TO; Jones DA
    Mol Pharmacol; 2001 Apr; 59(4):751-7. PubMed ID: 11259619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene.
    Beauséjour CM; Eliopoulos N; Momparler L; Le NL; Momparler RL
    Cancer Gene Ther; 2001 Sep; 8(9):669-76. PubMed ID: 11593336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia.
    Lemaire M; Momparler LF; Bernstein ML; Marquez VE; Momparler RL
    Anticancer Drugs; 2005 Mar; 16(3):301-8. PubMed ID: 15711182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
    Bender CM; Pao MM; Jones PA
    Cancer Res; 1998 Jan; 58(1):95-101. PubMed ID: 9426064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase.
    Raynal NJ; Momparler LF; Rivard GE; Momparler RL
    Leuk Res; 2011 Jan; 35(1):110-8. PubMed ID: 20510451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase.
    Momparler RL; Doré BT; Labiberté J; Momparler LF
    Leukemia; 1993 May; 7 Suppl 1():17-20. PubMed ID: 7683351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.
    Lemaire M; Momparler LF; Raynal NJ; Bernstein ML; Momparler RL
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):411-6. PubMed ID: 18398609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer.
    Momparler RL; Bouffard DY; Momparler LF; Dionne J; Belanger K; Ayoub J
    Anticancer Drugs; 1997 Apr; 8(4):358-68. PubMed ID: 9180389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine).
    Momparler RL
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S9-16. PubMed ID: 16015507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of 5-Aza-CdR on transcription regulation of RASSF1A gene in the BIU87 cell line.
    Liu X; Dai X; Wu B
    Urol Int; 2009; 82(1):108-12. PubMed ID: 19172108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine.
    Karpf AR; Lasek AW; Ririe TO; Hanks AN; Grossman D; Jones DA
    Mol Pharmacol; 2004 Jan; 65(1):18-27. PubMed ID: 14722233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells.
    Pulukuri SM; Rao JS
    Int J Oncol; 2005 Apr; 26(4):863-71. PubMed ID: 15753979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
    Bai T; Tanaka T; Yukawa K; Umesaki N
    Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation.
    Samlowski WE; Leachman SA; Wade M; Cassidy P; Porter-Gill P; Busby L; Wheeler R; Boucher K; Fitzpatrick F; Jones DA; Karpf AR
    J Clin Oncol; 2005 Jun; 23(17):3897-905. PubMed ID: 15753459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Growth and gene expression of leukemia cell after treated with methylation inhibitor 5-aza-2'-deoxycytidine].
    Qiao SK; Xu SR; Guo XN
    Zhonghua Xue Ye Xue Za Zhi; 2004 Aug; 25(8):486-90. PubMed ID: 15555266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible involvement of activation of P53/P21 and demethylation of RUNX 3 in the cytotoxicity against Lovo cells induced by 5-Aza-2'-deoxycytidine.
    Deng T; Zhang Y
    Life Sci; 2009 Feb; 84(9-10):311-20. PubMed ID: 19159630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.